Table of Content

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.2.1 MARKETS COVERED 16
1.2.2 YEARS CONSIDERED FOR THE STUDY 16
1.3 CURRENCY 17
1.4 LIMITATIONS 17
1.5 STAKEHOLDERS 17

2 RESEARCH METHODOLOGY 18
2.1 RESEARCH DATA 18
2.1.1 SECONDARY DATA 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 21
2.1.2.1 Breakdown of primaries 21
2.1.2.2 Key data from primary sources 22
2.2 MARKET SIZE ESTIMATION 23
2.2.1 PRODUCT-BASED MARKET ESTIMATION 23
2.2.2 END USER-BASED MARKET SIZE ESTIMATION 24
2.2.3 PRIMARY RESEARCH VALIDATION 25
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 26
2.4 ASSUMPTIONS FOR THE STUDY 27
2.5 RESEARCH LIMITATIONS 27

3 EXECUTIVE SUMMARY 28

4 PREMIUM INSIGHTS 32
4.1 FIDUCIAL MARKERS: MARKET OVERVIEW 32
4.2 FIDUCIAL MARKERS MARKET, BY PRODUCT & REGION, 2019 33
4.3 FIDUCIAL MARKERS MARKET, BY MODALITY, 2019–2025 34
4.4 FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2019 VS. 2025 35
4.5 FIDUCIAL MARKERS MARKET SHARE, BY END USER, 2019 VS. 2025 36
4.6 GEOGRAPHIC SNAPSHOT OF THE FIDUCIAL MARKERS MARKET, 2019 36

5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
5.2.1 DRIVERS 38
5.2.1.1 Growing incidence of cancer 38
5.2.1.2 Improving reimbursement scenario 38
5.2.1.3 Rising awareness on radiotherapy 39
5.2.1.4 Rising investments and funding for cancer research 40
5.2.2 RESTRAINTS 40
5.2.2.1 Lack of adequate healthcare infrastructure and premium pricing of modalities 40
5.2.2.2 Alternative therapies and high marker costs 41
5.2.3 OPPORTUNITIES 41
5.2.3.1 Emerging economies 41
5.2.4 CHALLENGES 42
5.2.4.1 Complications associated with the placement of fiducial markers 42
5.2.4.2 Shortage of trained personnel 42

6 FIDUCIAL MARKERS MARKET, BY PRODUCT 43
6.1 INTRODUCTION 44
6.2 METAL-BASED MARKERS 44
6.2.1 PURE GOLD MARKERS 46
6.2.1.1 Pure gold markers hold the largest share of the metal-based fiducial markers market 46
6.2.2 GOLD COMBINATION MARKERS 48
6.2.2.1 High-precision advantages and versatility are driving demand for gold combination markers 48
6.2.3 OTHER METAL-BASED MARKERS 49
6.3 POLYMER-BASED MARKERS 51
6.3.1 VISIBILITY LIMITATIONS HAVE AFFECTED DEMAND FOR POLYMER-BASED MARKERS 51
6.4 OTHER FIDUCIAL MARKERS 53

7 FIDUCIAL MARKERS MARKET, BY MODALITY 55
7.1 INTRODUCTION 56
7.2 CT/CBCT 56
7.2.1 TECHNOLOGICAL ADVANCEMENTS AND RISING ADOPTION OF CBCT ARE EXPECTED TO FUEL MARKET GROWTH 56
7.3 ULTRASOUND 57
7.3.1 RISING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES IS DRIVING DEMAND FOR ULTRASOUND 57
7.4 MRI 58
7.4.1 HIGH ADOPTION OF COMBINED CT-MRI MODALITIES FOR FM LOCALIZATION WILL DRIVE SEGMENTAL GROWTH 58
7.5 RADIOTHERAPY 59
7.5.1 HIGH SUCCESS RATE OF SBRT USING RADIOTHERAPY SYSTEMS WILL DRIVE THE SEGMENT GROWTH 59
?

8 FIDUCIAL MARKERS MARKET, BY CANCER TYPE 61
8.1 INTRODUCTION 62
8.2 PROSTATE CANCER 62
8.2.1 PROSTATE CANCER HOLDS THE LARGEST SHARE OF THE MARKET, BY CANCER TYPE 62
8.3 LUNG CANCER 64
8.3.1 TECHNOLOGICAL ADVANCEMENTS AND PRODUCT APPROVALS WILL DRIVE MARKET GROWTH 64
8.4 GASTRIC CANCER 65
8.4.1 HIGH INCIDENCE OF GASTRIC CANCER AND ADVANCEMENTS IN TREATMENT SUPPORT MARKET GROWTH 65
8.5 BREAST CANCER 66
8.5.1 EFFICACY OF ADVANCED RADIOLOGY TREATMENT FOR BREAST CANCER WILL ENSURE THE GROWTH OF THE MARKET 66
8.6 OTHER CANCERS 68

9 FIDUCIAL MARKERS MARKET, BY END USER 69
9.1 INTRODUCTION 70
9.2 HOSPITALS & OUTPATIENT FACILITIES 70
9.2.1 HOSPITALS & OUTPATIENT FACILITIES HOLD THE LARGEST SHARE OF THE MARKET 70
9.3 INDEPENDENT RADIOTHERAPY CENTERS 71
9.3.1 UNFAVORABLE REIMBURSEMENT SCENARIO WILL HAMPER GROWTH 71
9.4 CANCER RESEARCH CENTERS 72
9.4.1 RISING INVESTMENTS AND FUNDING WILL INCREASE RESEARCH ACTIVITIES AND SUPPORT MARKET GROWTH 72

10 FIDUCIAL MARKERS MARKET, BY REGION 74
10.1 INTRODUCTION 75
10.2 NORTH AMERICA 75
10.2.1 US 78
10.2.1.1 US commanded the largest share of the market in 2018 78
10.2.2 CANADA 80
10.2.2.1 Public-private initiatives are expected to support the adoption of radiotherapy procedures and fiducial markers 80
10.3 EUROPE 81
10.3.1 GERMANY 84
10.3.1.1 Favorable reimbursement scenario for radiotherapy is supporting market growth in Germany 84
10.3.2 UK 85
10.3.2.1 Rising cancer incidence and the presence of highly developed healthcare infrastructure are supporting market growth in the UK 85
10.3.3 FRANCE 86
10.3.3.1 Increasing access to radiotherapy will drive market growth 86
10.3.4 SPAIN 87
10.3.4.1 Shortage of human resources and lack of accessibility may hinder market growth 87
10.3.5 ITALY 88
10.3.5.1 Rising research activities will support market growth 88
10.3.6 REST OF EUROPE 89
10.4 ASIA PACIFIC 90
10.4.1 JAPAN 92
10.4.1.1 Japan dominates the APAC fiducial markers market 92
10.4.2 CHINA 94
10.4.2.1 China will register the highest growth in the APAC fiducial markers market due to the growing target patient population 94
10.4.3 INDIA 95
10.4.3.1 Indian market is expected to be driven by the surge in patient population and favorable government initiatives 95
10.4.4 SOUTH KOREA 96
10.4.4.1 Growing adoption of advanced EBRT is contributing to market growth in the country 96
10.4.5 AUSTRALIA 97
10.4.5.1 Favorable reimbursement scenario will support market growth 97
10.4.6 REST OF APAC 98
10.5 LATIN AMERICA 99
10.5.1 BRAZIL 102
10.5.1.1 Brazil held the largest share of the Latin American fiducial markers market in 2018 102
10.5.2 MEXICO 103
10.5.2.1 Initiatives are being undertaken to spread awareness and boost access to radiotherapy 103
10.5.3 REST OF LATAM 104
10.6 MIDDLE EAST & AFRICA 105
10.6.1 POOR HEALTHCARE INFRASTRUCTURE AND REIMBURSEMENT SCENARIO RESTRAIN MARKET GROWTH 105

11 COMPETITIVE LANDSCAPE 108
11.1 OVERVIEW 108
11.2 MARKET SHARE ANALYSIS 109
11.3 COMPETITIVE SCENARIO 110
11.3.1 KEY PRODUCT LAUNCHES AND ENHANCEMENTS 110
11.3.2 KEY AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 110
11.3.3 KEY ACQUISITIONS 110
11.3.4 KEY EXPANSIONS 110
?
11.4 COMPETITIVE LEADERSHIP MAPPING 111
11.4.1 VISIONARY LEADERS 112
11.4.2 INNOVATORS 112
11.4.3 DYNAMIC DIFFERENTIATORS 112
11.4.4 EMERGING COMPANIES 112

12 COMPANY PROFILES 114
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 CIVCO RADIOTHERAPY 114
12.2 BOSTON SCIENTIFIC CORPORATION 116
12.3 IZI MEDICAL PRODUCTS 118
12.4 IBA 120
12.5 NASLUND MEDICAL AB 122
12.6 MEDTRONIC 123
12.7 BEST MEDICAL INTERNATIONAL, INC. 125
12.8 NANOVI A/S 126
12.9 CARBON MEDICAL TECHNOLOGIES 127
12.10 ECKERT & ZIEGLER 128
12.11 INNOVATIVE ONCOLOGY SOLUTIONS 130
12.12 QLRAD INC. 131
12.13 STELLAR MEDICAL 132
12.14 JJ-MEDTECH 133
12.15 QFIX 134
12.16 OTHER COMPANIES 135
12.16.1 VARIAN MEDICAL SYSTEMS, INC. 135
12.16.2 BEEKLEY CORPORATION 135
12.16.3 INNOMEDICUS AG 136
12.16.4 MEDITRONIX CORPORATION 136
12.16.5 SEEDOS LTD 137
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 138
13.1 DISCUSSION GUIDE 138
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL 143
13.3 AVAILABLE CUSTOMIZATIONS 145
13.4 RELATED REPORTS 145
13.5 AUTHOR DETAILS 146



List of Figures



FIGURE 1 FIDUCIAL MARKERS MARKET: RESEARCH METHODOLOGY STEPS 18
FIGURE 2 RESEARCH DESIGN 19
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE DESIGNATION, AND REGION 21
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 22
FIGURE 5 FIDUCIAL MARKERS MARKET: PRODUCT-BASED ESTIMATION 24
FIGURE 6 FIDUCIAL MARKERS MARKET: END USER-BASED ESTIMATION 25
FIGURE 7 FIDUCIAL MARKERS MARKET: DATA TRIANGULATION 26
FIGURE 8 FIDUCIAL MARKERS MARKET SHARE, BY PRODUCT, 2019 VS. 2025 28
FIGURE 9 FIDUCIAL MARKERS MARKET SHARE, BY MODALITY, 2019 VS. 2025 29
FIGURE 10 FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2019–2025 (USD MILLION) 29
FIGURE 11 FIDUCIAL MARKERS MARKET, BY END USER, 2019–2025 (USD MILLION) 30
FIGURE 12 FIDUCIAL MARKERS MARKET, BY REGION: GEOGRAPHICAL SNAPSHOT 31
FIGURE 13 GROWING ADOPTION OF IMAGE-GUIDED RADIOTHERAPY ACROSS THE GLOBE IS SUPPORTING THE GROWTH OF THE MARKET 32
FIGURE 14 METAL-BASED MARKERS COMMAND THE LARGEST MARKET SHARE 33
FIGURE 15 CT/CBCT SEGMENT DOMINATES THE GLOBAL MARKET DURING
THE FORECAST PERIOD 34
FIGURE 16 PROSTATE CANCER SEGMENT WILL HOLD THE MAJOR SHARE OF THE MARKET DURING THE FORECAST PERIOD 35
FIGURE 17 HOSPITALS & OUTPATIENT FACILITIES SEGMENT COMMAND THE LARGEST MARKET SHARE 36
FIGURE 18 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 36
FIGURE 19 FIDUCIAL MARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 37
FIGURE 20 NUMBER OF NEW CANCER CASES DIAGNOSED, BY COUNTRY, 2018 (THOUSAND) 38
FIGURE 21 NORTH AMERICA: FIDUCIAL MARKERS MARKET SNAPSHOT 76
FIGURE 22 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019 108
FIGURE 23 CIVCO RADIOTHERAPY HELD THE LEADING POSITION IN THE FIDUCIAL MARKERS MARKET, 2018 109
FIGURE 24 FIDUCIAL MARKERS MARKET (GLOBAL) COMPETITIVE LEADERSHIP
MAPPING, 2019 113
FIGURE 25 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 116
FIGURE 26 IBA: COMPANY SNAPSHOT 120
FIGURE 27 MEDTRONIC: COMPANY SNAPSHOT 123
FIGURE 28 ECKERT & ZIEGLER: COMPANY SNAPSHOT 128

 

List of Tables



TABLE 1 NATIONAL AVERAGE MEDICARE REIMBURSEMENT: OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS) ESTIMATED PER COURSE 39
TABLE 2 REIMBURSEMENT FOR IMRT IN GERMANY, 2017 39
TABLE 3 FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 44
TABLE 4 METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION) 44
TABLE 5 METAL-BASED FIDUCIAL MARKERS MARKET, BY REGION 2017–2025 (USD MILLION) 45
TABLE 6 METAL-BASED FIDUCIAL MARKERS MARKET, BY MODALITY 2017–2025 (USD MILLION) 45
TABLE 7 METAL-BASED FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 45
TABLE 8 METAL-BASED FIDUCIAL MARKERS MARKET, BY END USER 2017–2025 (USD MILLION) 46
TABLE 9 PURE GOLD FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION) 46
TABLE 10 PURE GOLD FIDUCIAL MARKERS MARKET, BY MODALITY 2017–2025 (USD MILLION) 47
TABLE 11 PURE GOLD FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 47
TABLE 12 PURE GOLD FIDUCIAL MARKERS MARKET, BY END USER 2017–2025 (USD MILLION) 47
TABLE 13 GOLD COMBINATION FIDUCIAL MARKERS MARKET, BY REGION 2017–2025 (USD MILLION) 48
TABLE 14 GOLD COMBINATION FIDUCIAL MARKERS MARKET, BY MODALITY 2017–2025 (USD MILLION) 48
TABLE 15 GOLD COMBINATION FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 49
TABLE 16 GOLD COMBINATION FIDUCIAL MARKERS MARKET, BY END USER 2017–2025 (USD MILLION) 49
TABLE 17 OTHER METAL-BASED FIDUCIAL MARKERS MARKET, BY REGION 2017–2025 (USD MILLION) 50
TABLE 18 OTHER METAL-BASED FIDUCIAL MARKERS MARKET, BY MODALITY 2017–2025 (USD MILLION) 50
TABLE 19 OTHER METAL-BASED FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 51
TABLE 20 OTHER METAL-BASED FIDUCIAL MARKERS MARKET, BY END USER 2017–2025 (USD MILLION) 51
TABLE 21 POLYMER-BASED FIDUCIAL MARKERS MARKET, BY REGION 2017–2025 (USD MILLION) 52
TABLE 22 POLYMER-BASED FIDUCIAL MARKERS MARKET, BY MODALITY 2017–2025 (USD MILLION) 52
TABLE 23 POLYMER-BASED FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 52
TABLE 24 POLYMER-BASED FIDUCIAL MARKERS MARKET, BY END USER 2017–2025 (USD MILLION) 53
TABLE 25 OTHER FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION) 53
TABLE 26 OTHER FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION) 54
TABLE 27 OTHER FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 54
TABLE 28 OTHER FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION) 54
TABLE 29 FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION) 56
TABLE 30 FIDUCIAL MARKERS MARKET FOR CT/CBCT, BY REGION 2017–2025 (USD MILLION) 57
TABLE 31 FIDUCIAL MARKERS MARKET FOR ULTRASOUND, BY REGION 2017–2025 (USD MILLION) 58
TABLE 32 FIDUCIAL MARKERS MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 2017–2025 (USD MILLION) 58
TABLE 33 CONVENTIONAL EBRT VS SBRT 59
TABLE 34 FIDUCIAL MARKERS MARKET FOR RADIOTHERAPY, BY REGION 2017–2025 (USD MILLION) 60
TABLE 35 FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION) 62
TABLE 36 NEWLY DIAGNOSED PROSTATE CANCER CASES, BY KEY COUNTRY, 2018 63
TABLE 37 FIDUCIAL MARKERS MARKET FOR PROSTATE CANCER, BY REGION 2017–2025 (USD MILLION) 63
TABLE 38 FIDUCIAL MARKERS MARKET FOR LUNG CANCER, BY REGION 2017–2025 (USD MILLION) 64
TABLE 39 NEW GASTRIC CANCER CASES DIAGNOSED, BY COUNTRY, 2018 65
TABLE 40 FIDUCIAL MARKERS MARKET FOR GASTRIC CANCER, BY REGION 2017–2025 (USD MILLION) 66
TABLE 41 NEW BREAST CANCER CASES DIAGNOSED, BY COUNTRY, 2018 67
TABLE 42 FIDUCIAL MARKERS MARKET FOR BREAST CANCER, BY REGION 2017–2025 (USD MILLION) 67
TABLE 43 FIDUCIAL MARKERS MARKET FOR OTHER CANCERS, BY REGION 2017–2025 (USD MILLION) 68
TABLE 44 FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION) 70
TABLE 45 FIDUCIAL MARKERS MARKET FOR HOSPITALS & OUTPATIENT FACILITIES BY REGION, 2017–2025 (USD MILLION) 71
TABLE 46 FIDUCIAL MARKERS MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS BY REGION, 2017–2025 (USD MILLION) 72
TABLE 47 FIDUCIAL MARKERS MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 2017–2025 (USD MILLION) 73
TABLE 48 FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION) 75
TABLE 49 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY COUNTRY 2017–2025 (USD MILLION) 76
TABLE 50 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 77
TABLE 51 NORTH AMERICA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 77
TABLE 52 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY MODALITY 2017–2025 (USD MILLION) 77
TABLE 53 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 78
TABLE 54 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY END USER 2017–2025 (USD MILLION) 78
TABLE 55 NATIONAL AVERAGE MEDICARE REIMBURSEMENT: OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS) ESTIMATED PER COURSE 79
TABLE 56 NCI FUNDING, BY RESEARCH AREA, 2015–2017 (USD MILLION) 79
TABLE 57 US: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 79
TABLE 58 US: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 80
TABLE 59 CANADA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 80
TABLE 60 CANADA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 81
TABLE 61 EUROPE: FIDUCIAL MARKERS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 82
TABLE 62 EUROPE: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 82
TABLE 63 EUROPE: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 82
TABLE 64 EUROPE: FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION) 83
TABLE 65 EUROPE: FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 83
TABLE 66 EUROPE: FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION) 83
TABLE 67 GERMANY: FIDUCIAL MARKERS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 84
TABLE 68 GERMANY: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 84
TABLE 69 UK: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 85
TABLE 70 UK: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 85
TABLE 71 FRANCE: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 86
TABLE 72 FRANCE: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 86
TABLE 73 SPAIN: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 87
TABLE 74 SPAIN: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 87
TABLE 75 ITALY: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 88
TABLE 76 ITALY: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 88
TABLE 77 ROE: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 89
TABLE 78 ROE: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 90
TABLE 79 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY COUNTRY 2017–2025 (USD MILLION) 90
TABLE 80 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 91
TABLE 81 ASIA PACIFIC: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 91
TABLE 82 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY MODALITY 2017–2025 (USD MILLION) 91
TABLE 83 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 92
TABLE 84 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY END USER 2017–2025 (USD MILLION) 92
TABLE 85 JAPAN: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 93
TABLE 86 JAPAN: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 93
TABLE 87 CHINA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 94
TABLE 88 CHINA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 95
TABLE 89 INDIA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 96
TABLE 90 INDIA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 96
TABLE 91 SOUTH KOREA: FIDUCIAL MARKERS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 97
TABLE 92 SOUTH KOREA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 97
TABLE 93 AUSTRALIA: FIDUCIAL MARKERS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 98
TABLE 94 AUSTRALIA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 98
TABLE 95 ROAPAC: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 99
TABLE 96 ROAPAC: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 99
TABLE 97 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY COUNTRY 2017–2025 (USD MILLION) 100
TABLE 98 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 100
TABLE 99 LATIN AMERICA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 100
TABLE 100 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY MODALITY 2017–2025 (USD MILLION) 101
TABLE 101 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY CANCER TYPE 2017–2025 (USD MILLION) 101
TABLE 102 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY END USER 2017–2025 (USD MILLION) 101
TABLE 103 BRAZIL: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 102
TABLE 104 BRAZIL: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 102
TABLE 105 MEXICO: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 103
TABLE 106 MEXICO: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 104
TABLE 107 ROLA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 104
TABLE 108 ROLA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 105
TABLE 109 MEA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 105
TABLE 110 MEA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE 2017–2025 (USD MILLION) 106
TABLE 111 MEA: FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION) 106
TABLE 112 MEA: FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION) 106
TABLE 113 MEA: FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION) 107